Figure 2E shows that the CD4+/CD8+ T cell ratio was significantly reduced in advanced-stage DLBCL patients (1.10 vs 1.28, p = 0.001). Finally, as shown in Figure 2F, there was no significant difference in the percentage of CD16+CD56+ NK cells between the two groups. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.